Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8) (LS2.008)

Amanda L. Piquet; Αναστασία Ζεκερίδου; Usama Gergis; Jonathan Gutman; Saad S. Kenderian; Mallory Lowe; Sadie Eggmann; Andrew McKeon; Sean J. Pittock; Goran Rakočević; Jessica J. Yi; Scott D. Newsome; Justin Chou; Tom Van Blarcom; Xue Han; John Sun; Shouvonik Sengupta; Ryan Tooker; Aditi Mehta; Dena Grayson; N. Gehchan; Marinos C. Dalakas

doi:10.1212/wnl.0000000000217905

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Evaluates miv-cel efficacy in stiff person syndrome, suggesting promising therapeutic potential.

Abstract

To evaluate the efficacy and safety of miv-cel (mivocabtagene autoleucel; formerly KYV-101) in patients with stiff person syndrome (SPS) in the pivotal, multicenter, phase 2 study, KYSA-8 (NCT06588491).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Piquet et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf403faef96ed7f05668d https://doi.org/10.1212/wnl.0000000000217905

View at Publisher

Ask AI

Bookmark

Share

Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8) (LS2.008)

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8) (LS2.008)

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading